ICE Stock Cash Flow Statements

Intercontinental Exchange Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Intercontinental Exchange Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31

operating activities:
net income	865,000,000	812,000,000	709,000,000	671,000,000	639,000,000	783,000,000	390,000,000	559,000,000	815,000,000	674,000,000	440,000,000	-175,000,000	566,000,000	667,000,000	1,529,000,000	637,000,000	1,253,000,000	650,000,000	528,000,000	394,000,000	528,000,000	658,000,000	453,000,000	537,000,000	478,000,000	492,000,000	619,000,000	465,000,000	462,000,000	474,000,000	1,231,000,000	375,000,000	426,000,000	510,000,000	359,000,000	350,000,000	363,000,000	377,000,000	373,000,000	310,000,000	289,000,000	323,000,000	294,000,000	213,000,000	234,000,000	275,000,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	395,000,000	389,000,000	389,000,000	386,000,000	381,000,000	381,000,000	379,000,000	309,000,000	267,000,000	260,000,000	263,000,000	258,000,000	256,000,000	254,000,000	250,000,000	253,000,000	251,000,000	255,000,000	257,000,000	180,000,000	157,000,000	157,000,000	189,000,000	158,000,000	157,000,000	158,000,000	157,000,000	148,000,000	143,000,000	138,000,000	131,000,000	128,000,000	142,000,000	134,000,000	140,000,000	181,000,000	146,000,000	143,000,000	98,000,000	94,000,000	93,000,000	89,000,000	89,000,000	83,000,000	73,000,000	88,000,000
stock-based compensation	58,000,000	57,000,000	60,000,000	57,000,000	57,000,000	57,000,000	93,000,000	79,000,000	45,000,000	40,000,000	39,000,000	40,000,000	38,000,000	38,000,000	76,000,000	39,000,000	37,000,000	36,000,000	34,000,000	32,000,000	32,000,000	41,000,000	39,000,000	36,000,000	35,000,000	29,000,000	37,000,000	32,000,000	32,000,000	29,000,000	33,000,000	34,000,000	34,000,000	34,000,000	34,000,000	30,000,000	31,000,000	29,000,000	32,000,000	32,000,000	23,000,000	24,000,000	24,000,000	24,000,000	27,000,000	22,000,000
deferred taxes	-49,000,000	-60,000,000	57,000,000	-83,000,000	-66,000,000	-50,000,000	-82,000,000	-8,000,000	-156,000,000	-83,000,000	-78,000,000	-368,000,000	-61,000,000	-86,000,000	403,000,000	-20,000,000	176,000,000	-22,000,000	25,000,000	69,000,000	1,000,000	-3,000,000	19,000,000	-10,000,000	-14,000,000	-28,000,000	29,000,000	5,000,000	-1,000,000	-6,000,000	-709,000,000	69,000,000	-39,000,000	28,000,000	94,000,000	-29,000,000	19,000,000	30,000,000	-45,000,000	-25,000,000	-14,000,000	-24,000,000	78,000,000	-29,000,000	-2,000,000	-26,000,000
(gain)/loss on investments
net (income)/losses from unconsolidated investees	-6,000,000	-29,000,000
other	13,000,000	14,000,000	7,000,000	17,000,000	17,000,000	14,000,000	9,000,000	28,000,000	16,000,000	10,000,000	10,000,000	10,000,000	12,000,000	9,000,000	51,000,000	4,000,000	0	-10,000,000	23,000,000	-38,000,000	1,000,000	-11,000,000	-6,000,000	-8,000,000	-5,000,000	-21,000,000	-13,000,000	-7,000,000	-5,000,000	1,000,000	-9,000,000	-6,000,000	-6,000,000	-1,000,000	-8,000,000	-2,000,000	1,000,000	3,000,000	-1,000,000	1,000,000	-2,000,000	-15,000,000	-3,000,000	-14,000,000	-19,000,000	-10,000,000
changes in assets and liabilities:
customer accounts receivable	231,000,000	-387,000,000	61,000,000	-17,000,000	92,000,000	-285,000,000	41,000,000	69,000,000	303,000,000	-484,000,000	92,000,000	105,000,000	303,000,000	-480,000,000	104,000,000	-35,000,000	229,000,000	-303,000,000	79,000,000	77,000,000	295,000,000	-600,000,000	67,000,000	-1,000,000	131,000,000	-227,000,000	75,000,000	29,000,000	111,000,000	-259,000,000	18,000,000	17,000,000	70,000,000	-240,000,000	23,000,000	69,000,000	72,000,000	-229,000,000	17,000,000	29,000,000	31,000,000	-122,000,000	43,000,000	-14,000,000	-33,000,000	-74,000,000
other current and non-current assets	62,000,000	-38,000,000	-22,000,000	-33,000,000	25,000,000	-76,000,000	-6,000,000	31,000,000	22,000,000	-88,000,000	-26,000,000	-122,000,000	8,000,000	-56,000,000	-37,000,000	16,000,000	29,000,000	-108,000,000	-40,000,000	-4,000,000	-4,000,000	-35,000,000	-39,000,000	19,000,000	-12,000,000	15,000,000	-21,000,000	15,000,000	-7,000,000	-32,000,000	5,000,000	8,000,000	-34,000,000	-3,000,000	15,000,000	13,000,000	-8,000,000	-13,000,000	15,000,000	5,000,000	1,000,000	-26,000,000	-5,000,000	29,000,000	58,000,000	-12,000,000
section 31 fees payable	149,000,000	-56,000,000	241,000,000	-128,000,000	137,000,000	-13,000,000	61,000,000	-155,000,000	55,000,000	-105,000,000	165,000,000	-114,000,000	122,000,000	-7,000,000	43,000,000	-149,000,000	40,000,000	-84,000,000	154,000,000	-263,000,000	151,000,000	27,000,000	104,000,000	-133,000,000	98,000,000	-35,000,000	84,000,000	-197,000,000	88,000,000	-8,000,000	97,000,000	-150,000,000	91,000,000	-40,000,000	97,000,000	-162,000,000	98,000,000	-19,000,000	85,000,000	-137,000,000	76,000,000	-45,000,000
deferred revenue	-106,000,000	370,000,000	-140,000,000	-129,000,000	-97,000,000	393,000,000	-143,000,000	-152,000,000	-127,000,000	406,000,000	-157,000,000	-162,000,000	-119,000,000	411,000,000	-129,000,000	-116,000,000	-96,000,000	375,000,000	-118,000,000	-133,000,000	-119,000,000	372,000,000	-132,000,000	-115,000,000	-118,000,000	347,000,000	-123,000,000	-125,000,000	-94,000,000	343,000,000	-116,000,000	-108,000,000	-87,000,000	328,000,000	-102,000,000	-113,000,000	-81,000,000	338,000,000	-104,000,000	-106,000,000	-75,000,000	312,000,000	-79,000,000	-89,000,000	-94,000,000	320,000,000
other current and non-current liabilities	-104,000,000	-106,000,000	145,000,000	141,000,000	8,000,000	-240,000,000	40,000,000	-26,000,000	-118,000,000	-12,000,000	156,000,000	170,000,000	-130,000,000	-36,000,000	80,000,000	-72,000,000	181,000,000	-55,000,000	179,000,000	123,000,000	-184,000,000	-86,000,000	83,000,000	17,000,000	-22,000,000	-76,000,000	64,000,000	134,000,000	-66,000,000	-107,000,000	104,000,000	-55,000,000	-172,000,000	37,000,000	-11,000,000	68,000,000	-135,000,000	-62,000,000	-49,000,000	-83,000,000	-106,000,000	-39,000,000	102,000,000	-283,000,000	158,000,000	29,000,000
total adjustments	641,000,000	154,000,000	797,000,000	227,000,000	557,000,000	226,000,000	579,000,000	209,000,000	337,000,000	-21,000,000	652,000,000	912,000,000	403,000,000	89,000,000	-536,000,000	-114,000,000	-380,000,000	84,000,000	538,000,000	43,000,000	330,000,000	-138,000,000	324,000,000	-37,000,000	250,000,000	162,000,000	179,000,000	34,000,000	201,000,000	99,000,000	-556,000,000	-63,000,000	61,000,000	101,000,000	282,000,000	55,000,000	143,000,000	220,000,000	48,000,000	-190,000,000	16,000,000	142,000,000	247,000,000	-137,000,000	102,000,000	246,000,000
net cash from operating activities	1,506,000,000	966,000,000	1,506,000,000	898,000,000	1,196,000,000	1,009,000,000	969,000,000	768,000,000	1,152,000,000	653,000,000	1,092,000,000	737,000,000	969,000,000	756,000,000	993,000,000	523,000,000	873,000,000	734,000,000	1,066,000,000	437,000,000	858,000,000	520,000,000	777,000,000	500,000,000	728,000,000	654,000,000	798,000,000	499,000,000	663,000,000	573,000,000	675,000,000	312,000,000	487,000,000	611,000,000		405,000,000	506,000,000	597,000,000
investing activities:
capital expenditures	-60,000,000	-85,000,000	-194,000,000	-79,000,000	-75,000,000	-58,000,000	-86,000,000	-43,000,000	-40,000,000	-21,000,000	-100,000,000	-55,000,000	-34,000,000	-36,000,000	-62,000,000	-22,000,000	-55,000,000	-40,000,000	-93,000,000	-66,000,000	-33,000,000	-15,000,000	-66,000,000	-30,000,000	-31,000,000	-26,000,000	-85,000,000	-16,000,000	-19,000,000	-14,000,000	-84,000,000	-55,000,000	-49,000,000	-32,000,000	-84,000,000	-70,000,000	-65,000,000	-31,000,000	-65,000,000	-33,000,000	-53,000,000	-39,000,000	-67,000,000	-47,000,000	-27,000,000	-31,000,000
free cash flows	1,446,000,000	881,000,000	1,312,000,000	819,000,000	1,121,000,000	951,000,000	883,000,000	725,000,000	1,112,000,000	632,000,000	992,000,000	682,000,000	935,000,000	720,000,000	931,000,000	501,000,000	818,000,000	694,000,000	973,000,000	371,000,000	825,000,000	505,000,000	711,000,000	470,000,000	697,000,000	628,000,000	713,000,000	483,000,000	644,000,000	559,000,000	591,000,000	257,000,000	438,000,000	579,000,000		335,000,000	441,000,000	566,000,000
capitalized software development costs	-107,000,000	-104,000,000	-82,000,000	-87,000,000	-90,000,000	-87,000,000	-77,000,000	-80,000,000	-78,000,000	-64,000,000	-57,000,000	-66,000,000	-67,000,000	-67,000,000	-62,000,000	-66,000,000	-69,000,000	-76,000,000	-49,000,000	-58,000,000	-52,000,000	-44,000,000	-36,000,000	-39,000,000	-38,000,000	-39,000,000	-34,000,000	-37,000,000	-38,000,000	-37,000,000	-33,000,000	-35,000,000	-35,000,000	-34,000,000	-27,000,000	-27,000,000	-36,000,000	-25,000,000	-20,000,000	-23,000,000	-23,000,000	-21,000,000	-22,000,000	-16,000,000	-20,000,000	-20,000,000
purchases of invested margin deposits	-998,000,000	-2,344,000,000	-533,000,000	0	-322,000,000	-536,000,000	-228,000,000	-589,000,000	-308,000,000	-463,000,000	0	-5,504,000,000	-780,000,000	-651,000,000
proceeds from invested margin deposits
cash paid for acquisitions, net of cash acquired	-2,000,000	-11,000,000	-30,000,000	0			49,000,000	-10,242,000,000			-2,000,000	-21,000,000			-56,000,000	-4,000,000			-7,000,000	-9,188,000,000	-2,000,000	-249,000,000																					-427,000,000	0	-8,000,000	-142,000,000
proceeds from sale of promissory note			0	0	0	75,000,000
purchases of equity and equity method investments											-4,000,000	-26,000,000
purchases of restricted investments	-131,000,000	-183,000,000	-98,000,000	1,000,000	-591,000,000	-64,000,000
proceeds from restricted investments
net cash provided by/(used in) investing activities	1,068,000,000	-2,153,000,000														-94,000,000
financing activities:
proceeds from debt issuances			0	0
repayments of debt			0	0	-1,000,000,000	-600,000,000				-4,000,000
proceeds from commercial paper
repurchases of common stock	-255,000,000	-241,000,000									0	0	-157,000,000	-475,000,000					0	-148,000,000	-400,000,000	-699,000,000	-340,000,000	-340,000,000	-340,000,000	-440,000,000	-139,000,000	-300,000,000	-459,000,000	-300,000,000	-240,000,000	-240,000,000	-240,000,000	-229,000,000					-55,000,000	-206,000,000	-203,000,000	-196,000,000	-197,000,000
dividends paid to stockholders	-277,000,000	-278,000,000	-259,000,000	-261,000,000
change in cash and cash equivalent margin deposits and guaranty funds liability	2,182,000,000	2,999,000,000	3,899,000,000	-1,453,000,000	5,568,000,000	-4,551,000,000
payments relating to treasury shares received for restricted stock tax payments and stock option exercises	-3,000,000	-95,000,000	-4,000,000	-4,000,000	-2,000,000	-71,000,000	-25,000,000	-3,000,000	-1,000,000	-49,000,000	-1,000,000	-1,000,000	-2,000,000	-69,000,000	-1,000,000	-2,000,000	-2,000,000	-65,000,000	-2,000,000	0	-3,000,000	-69,000,000	-1,000,000	-4,000,000	-3,000,000	-57,000,000		-2,000,000	-4,000,000	-72,000,000	-3,000,000	-4,000,000	-4,000,000	-77,000,000	-3,000,000	-3,000,000	-1,000,000	-47,000,000	-3,000,000	-3,000,000	-3,000,000	-36,000,000	-6,000,000	-2,000,000	-1,000,000	-36,000,000
net cash provided by/(used in) financing activities	572,000,000	2,283,000,000							-15,535,000,000	-42,351,000,000
effect of exchange rate changes on cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds	25,000,000	10,000,000	-21,000,000	12,000,000	0	-5,000,000	14,000,000	-13,000,000	5,000,000	1,000,000
net increase in cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds
cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at beginning of period	0	84,503,000,000	0	0	0	80,750,000,000		0	0	150,343,000,000
cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at end of period	3,171,000,000	85,609,000,000	3,361,000,000	-1,494,000,000	6,145,000,000	76,491,000,000		-14,617,000,000	-15,279,000,000	110,691,000,000
supplemental cash flow disclosure:
cash paid for income taxes														90,000,000	248,000,000	395,000,000	283,000,000	131,000,000	84,000,000	83,000,000	348,000,000	127,000,000	100,000,000	161,000,000	218,000,000	78,000,000	109,000,000	78,000,000	202,000,000	144,000,000	83,000,000	82,000,000	364,000,000	65,000,000	98,000,000	87,000,000	219,000,000	56,000,000	123,000,000	186,000,000	182,000,000	51,000,000	73,000,000	50,000,000	169,000,000	46,000,000
cash paid for interest														117,000,000	77,000,000	118,000,000	83,000,000	128,000,000	89,000,000	60,000,000	80,000,000	69,000,000	66,000,000	69,000,000	66,000,000	79,000,000	66,000,000	32,000,000	77,000,000	27,000,000	72,000,000	12,000,000	80,000,000	7,000,000	81,000,000	1,000,000	81,000,000	7,000,000	33,000,000	1,000,000	88,000,000	1,000,000	33,000,000	6,000,000	96,000,000	5,000,000
reconciliation of the components of cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds to the consolidated balance sheets:
cash and cash equivalents																0
short-term restricted cash and cash equivalents
long-term restricted cash and cash equivalents
cash and cash equivalent margin deposits and guaranty funds
total
loss on investments				-2,000,000	0	3,000,000
proceeds from sales of invested margin deposits		481,000,000	9,000,000	98,000,000	760,000,000	230,000,000	578,000,000	318,000,000	473,000,000	2,605,000,000	3,198,000,000	470,000,000	2,106,000,000	1,709,000,000
proceeds from sales of restricted investments		100,000,000	-1,000,000	0	154,000,000	702,000,000
redemption of commercial paper		-96,000,000				-38,000,000						0
net increase/(decrease) in cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds		1,106,000,000	3,361,000,000	-1,494,000,000					-15,279,000,000	-39,652,000,000
fair value loss on promissory note
net incomees from and impairment of unconsolidated investees							31,000,000
proceeds from the sale of equity investments
proceeds from/(purchases of) other investments
other investing activities
(redemption of)/proceeds from commercial paper			-841,000,000
other financing activities
net incomees from unconsolidated investees				18,000,000	3,000,000	42,000,000			30,000,000	35,000,000
(purchases of)/proceeds from sale of equity and equity method investments
net cash from investing activities				-73,000,000	-187,000,000	259,000,000	606,000,000	-10,547,000,000	-901,000,000	2,045,000,000			1,961,000,000	882,000,000				-116,000,000	-128,000,000	-9,310,000,000	-90,000,000	-302,000,000	-82,000,000	-110,000,000	-362,000,000	-40,000,000	-138,000,000	-799,000,000	-63,000,000	-755,000,000	-35,000,000	-82,000,000	317,000,000	-108,000,000				-59,000,000
capital contributions from non-controlling interests
net cash from financing activities				-2,331,000,000	5,136,000,000	-5,522,000,000						-2,865,000,000	5,560,000,000	13,678,000,000			-1,935,000,000	-583,000,000	-965,000,000	8,598,000,000	-478,000,000	-411,000,000	-502,000,000	-469,000,000	-186,000,000	-596,000,000	-444,000,000	282,000,000	-571,000,000	270,000,000	-437,000,000	-213,000,000	-770,000,000	-551,000,000		-335,000,000	-334,000,000	-697,000,000
dividends to stockholders						-258,000,000	-242,000,000	-241,000,000	-236,000,000	-236,000,000	-213,000,000	-213,000,000	-213,000,000	-214,000,000	-186,000,000	-187,000,000	-187,000,000	-187,000,000	-169,000,000	-170,000,000	-164,000,000	-166,000,000	-154,000,000	-155,000,000	-155,000,000	-157,000,000	-138,000,000	-138,000,000	-139,000,000	-140,000,000
net decrease in cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds						-4,259,000,000
gain on deconsolidation of bakkt
(gains)/losses on sale of investments
proceeds from the sales of equity investments
proceeds from debt offerings
proceeds from/(redemption of) commercial paper							-303,000,000							256,000,000	-312,000,000			-343,000,000	-55,000,000	1,760,000,000
net cash (used in)/provided by financing activities							-1,634,000,000
net (decrease)/increase in cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds							-45,000,000
cash, cash equivalents, restricted cash and cash equivalents and cash and cash equivalent margin deposits and guaranty funds at beginning of year
cash, cash equivalents, restricted cash and cash equivalents and cash and cash equivalent margin deposits and guaranty funds at end of year
supplemental cash flow disclosures:
loss/(gain) on sale of investments
proceeds from sale of/(purchases of) equity and equity method investments
proceeds from sale of euroclear investment												0
purchases of investments								-7,000,000																			-1,000,000	0	-1,000,000	-304,000,000
proceeds from/(repayments of) debt facilities								518,000,000
change in cash and cash equivalent margin deposits and guaranty funds								-7,349,000,000	-15,321,000,000	-42,059,000,000	-17,996,000,000	-2,660,000,000	2,010,000,000	14,153,000,000
reconciliation of the components of cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds to the balance sheet:
gain on sale of euroclear investment												0
gains on equity investments
net incomees/(income) from and impairment of unconsolidated investees
proceeds from other investments
common stock issued for acquisition																			0
gain on sale of coinbase investment															0	0
gain on equity investments															0
net incomees/(income) from unconsolidated investees												1,055,000,000	15,000,000	42,000,000
impairment of bakkt investment
proceeds from sale of coinbase investment
proceeds from debt facilities												2,705,000,000							0	7,157,000,000			-1,000,000				0				-1,000,000
repayments of debt facilities															2,000,000				-746,000,000	-2,000,000							0				0														-929,000,000	-161,000,000
effect of exchange rate changes on cash and cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds												-22,000,000	-18,000,000	-1,000,000
net increase in cash and cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds												-7,354,000,000	8,472,000,000	15,315,000,000
cash and cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at beginning of period												0	0	147,976,000,000
cash and cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at end of period												-7,354,000,000	8,472,000,000	163,291,000,000
reconciliation of the components of cash and cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds to the balance sheet:
return of capital from equity method investment																							16,000,000	0	0	44,000,000
purchase of equity method investment															-94,000,000	0
proceeds from the sale of coinbase investment															0	0
proceeds from sale of invested margin deposits
cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at beginning of year
cash, cash equivalents, restricted cash and cash equivalents, and cash and cash equivalent margin deposits and guaranty funds at end of year
effect of exchange rate changes on cash, cash equivalents and restricted cash and cash equivalents																		-1,000,000		5,000,000	5,000,000	-9,000,000		-3,000,000	0	1,000,000		0	-7,000,000	2,000,000
net increase/(decrease) in cash, cash equivalents, and restricted cash and cash equivalents
cash, cash equivalents, and restricted cash and cash equivalents, beginning of period																0	0	1,991,000,000		0	0	2,188,000,000		0	0	1,872,000,000		0	0	1,568,000,000
cash, cash equivalents, and restricted cash and cash equivalents, end of period																15,000,000	21,000,000	2,025,000,000		-270,000,000	295,000,000	1,986,000,000		-82,000,000	180,000,000	1,891,000,000		-18,000,000	22,000,000	1,658,000,000
property and equipment																-2,000,000
goodwill																5,000,000
identifiable intangibles																0
other assets and liabilities																-3,000,000
deferred tax liabilities on identifiable intangibles																0
total purchase price allocation
net increase in cash, cash equivalents, and restricted cash and cash equivalents																	21,000,000	34,000,000	-20,000,000	-270,000,000	295,000,000	-202,000,000	199,000,000	-82,000,000	180,000,000	19,000,000	210,000,000	-18,000,000	22,000,000	90,000,000
total preliminary purchase price allocation
proceeds from investments																			-1,000,000	2,000,000	-3,000,000	6,000,000
gain on acquisition of remaining mers interest
purchases of equity investments
acquisition of non-controlling interest
proceeds from issuance of redeemable non-controlling interest
effect of exchange rate changes on cash, cash equivalents, and restricted cash and cash equivalents
cash, cash equivalents, and restricted cash and cash equivalents at beginning of year
cash, cash equivalents, and restricted cash and cash equivalents at end of year
standard/description
asu no. 2016-13, financial instruments - measurement of credit losses on financial instruments, applies to all financial instruments carried at amortized cost including held-to-maturity debt securities and accounts receivable. it requires financial assets carried at amortized cost to be presented at the net amount expected to be collected and requires entities to record credit losses through an allowance for credit losses on available-for-sale debt securities.
asu 2017-04, simplifying the test for goodwill impairment, removes the second step of the goodwill impairment test, which requires a hypothetical purchase price allocation if the fair value of a reporting unit is less than its carrying value. goodwill impairment will now be measured using the difference between the carrying value and the fair value of the reporting unit, and any loss recognized should not exceed the total amount of goodwill allocated to that reporting unit.
asu 2018-15, customer's accounting for implementation costs incurred in a cloud computing arrangement that is a service contract, helps entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement by providing guidance for determining when an arrangement includes a software license and is solely a hosted service. customers will now apply the same criteria for capitalizing implementation costs as they would for a software license arrangement. the guidance also prescribes the balance sheet, income statement, and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures.
asu no. 2019-12, simplifying the accounting for income taxes, eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. it clarifies that single-member limited liability companies, and other similar disregarded entities that are not subject to income tax, are not required to recognize an allocation of consolidated income tax expense in their separate financial statements. further, it simplifies the accounting for franchise taxes, enacted changes in tax laws or rates and transactions that result in a step-up in the tax basis of goodwill.
proceeds from commercial paper, net of repayments																						503,000,000			293,000,000	54,000,000
1.
cetip realized investment gain																															0	0	62,000,000	-176,000,000
trayport gain
proceeds from sale of cetip																															0	0
cash received from divestitures
proceeds from/(repayments of) commercial paper																							-7,000,000
acquisition of non-controlling interest and redeemable non-controlling interest																											0				-119,000,000	0
cash paid for acquisitions																								0	-333,000,000	-19,000,000
operating activities
investing activities
financing activities
repayments of commercial paper																											-248,000,000					24,000,000	-352,000,000	-117,000,000
payments relating to treasury shares
supplemental cash flow disclosure
supplemental non-cash investing and financing activity
treasury stock retirement
cash paid for acquisitions, net of cash received for divestiture																												-746,000,000	-5,000,000	-400,000,000
proceeds from (repayments of) commercial paper																													23,000,000	789,000,000								-543,000,000
amortization of fair market value premium on nyse notes																																							0	0	-11,000,000	-12,000,000
purchases of cost and equity method investments
proceeds from term deposits
dividends to shareholders																															-118,000,000	-119,000,000	-119,000,000	-120,000,000	-102,000,000	-102,000,000	-103,000,000	-102,000,000	-89,000,000	-84,000,000	-85,000,000	-73,000,000	-74,000,000	-74,000,000	-75,000,000	-76,000,000
purchase of subsidiary shares from non-controlling interest																																							0	0			0
supplemental non-cash investing and financing activities
common stock and vested stock options issued for acquisitions
cash received for divestitures																																-1,000,000
decrease (increase) in restricted cash and investments																																					-72,000,000	-3,000,000		3,000,000	-23,000,000	34,000,000
effect of exchange rate changes on cash and cash equivalents																																4,000,000	4,000,000	1,000,000	-4,000,000	2,000,000			-5,000,000	-1,000,000	3,000,000	-11,000,000	-19,000,000	-6,000,000	5,000,000	-1,000,000
net increase in cash and cash equivalents																																				68,000,000	-78,000,000	-159,000,000		9,000,000	-74,000,000	100,000,000			1,093,000,000	3,000,000
cash and cash equivalents, beginning of period																																0	0	407,000,000		0	0	627,000,000		0	0	652,000,000		0	0	961,000,000
cash and cash equivalents, end of period																																21,000,000	38,000,000	360,000,000		68,000,000	-78,000,000	468,000,000		9,000,000	-74,000,000	752,000,000		-1,419,000,000	1,093,000,000	964,000,000
increase in restricted cash and investments																																	-25,000,000	-64,000,000									-56,000,000	6,000,000	-51,000,000	-60,000,000
net decrease in cash and cash equivalents																																	38,000,000	-47,000,000
cash received for divestiture																																		22,000,000
less: income from discontinued operations, net of tax																																												10,000,000	-19,000,000	-2,000,000
income from continuing operations																																							373,000,000	310,000,000	289,000,000	323,000,000	294,000,000	223,000,000	215,000,000	273,000,000
adjustments to reconcile income from continuing operations to net cash from operating activities:
net cash from operating activities from continuing operations																																							421,000,000	120,000,000	305,000,000	465,000,000	541,000,000	86,000,000	317,000,000	519,000,000
proceeds from ipo and sale of euronext and sale of nyse technologies
proceeds from term deposits and sales of available-for-sale investments																																							5,000,000	0
purchases of term deposits and available-for-sale investments
net cash from investing activities from continuing operations																																							-4,144,000,000	-53,000,000	985,000,000	-86,000,000	-453,000,000	-1,162,000,000	1,900,000,000	-249,000,000
net cash from financing activities from continuing operations																																							3,668,000,000	-57,000,000	-1,367,000,000	-268,000,000	-55,000,000	-333,000,000	-1,019,000,000	-266,000,000
net cash from operating activities from discontinued operations																																											0	-4,000,000
net cash from investing activities from discontinued operations																																											0	0
net cash from financing activities from discontinued operations																																											0	0
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
decrease in restricted cash and investments
repayments of debt facilities and commercial paper																																				-225,000,000				237,000,000			216,000,000
distributions of profits to non-controlling interest																																				-11,000,000	-1,000,000	-9,000,000	-3,000,000	-7,000,000	-2,000,000	-15,000,000	-2,000,000	-12,000,000	-10,000,000	-9,000,000
net cash provide by (used in) investing activities
additional contribution to equity method investment
less/plus: (income) income from discontinued operations, net of tax
impairment loss on cetip investment
additional contribution to equity method investee																																							0	0	0	-60,000,000
proceeds from exercise of common stock options																																							5,000,000	4,000,000	6,000,000	4,000,000	3,000,000	5,000,000	3,000,000	2,000,000
proceeds from ipo of euronext
proceeds from sales of available-for-sale investments																																											0	26,000,000	18,000,000	10,000,000
purchases of available-for-sale investments																																												-1,302,000,000	4,000,000	-6,000,000
borrowings (repayments) of debt facilities and commercial paper																																										35,000,000
expense recognized on early payoff of debt
amortization of increase in fair market value of nyse notes
pre-payment related to early payoff of debt
excess tax benefits from stock-based compensation																																												-5,000,000	-4,000,000	-14,000,000
income taxes payable																																														67,000,000
accrued salaries and benefits																																												33,000,000	5,000,000	-144,000,000
proceeds from sale of euronext and sales of nyse technologies businesses
proceeds from sale of euronext
net change in cash and cash equivalents from discontinued operations
deferred revenue amortization
issuance costs for debt facilities
due to affiliate
proceeds from ice to capitalize company
issuance costs of debt facility
net increase in cash
cash, beginning of period
cash, end of period
item 3.

We provide you with 20 years of cash flow statements for Intercontinental Exchange stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Intercontinental Exchange stock. Explore the full financial landscape of Intercontinental Exchange stock with our expertly curated income statements.

The information provided in this report about Intercontinental Exchange stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.